Search results
10 sie 2021 · To our knowledge, this is the largest prospective study presenting admission serum levels of Igs (IgG, IgM, and IgA) in adult patients with COVID-19 with the entire range of disease severity. We observed that non-survivors had lower IgG levels than survivors, and that IgG deficient patients had higher mortality rates compared to non-deficient ...
1 lip 2023 · The seroprevalence of SARS-CoV-2 IgM and IgG in COVID-19 patients was 81 and 83% less than 7 days after symptom onset, both antibodies raised to 95% at 2 weeks. Approximately 8% of COVID-19 patients tested negative for IgM or IgG .
This study aims to measure immunoglobulin G (IgG) and immunoglobulin M (IgM) response after detection of Severe Acute Respiratory Syndrome coronavirus (SARS CoV-2) antigens in coronavirus disease 2019 (COVID-19) patients concerning the severity of symptoms.
29 kwi 2020 · Within 19 days after symptom onset, 100% of patients tested positive for antiviral immunoglobulin-G (IgG). Seroconversion for IgG and IgM occurred simultaneously or sequentially. Both IgG...
27 lut 2022 · In respiratory and gastrointestinal tracts, IgM and sIgA serve as the main mediator of mucosal immunity. These features make the intranasal delivery of IgM or IgA neutralizing antibodies feasible for the treatment of COVID-19.
17 lut 2021 · We demonstrated the kinetics of IgM and IgG SARS-CoV-2 antibodies in COVID-19 patients and the association between clinical classification and antibodies, which will contribute to the interpretation of IgM and IgG SARS-CoV-2 antibody tests and in predicting the outcomes of patients with COVID-19.
Serological tests for specific antibodies against SARS-CoV-2, including immunoglobulin M (IgM), IgG and IgA antibodies, have been developed as supplementary diagnostic methods as they can provide information about recent or prior infection (Peeling et al., 2020).
